In vivo bioluminescence imaging reveals copper deficiency in a murine model of nonalcoholic fatty liver disease

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 50, 2016, Pages 14219-14224

  Heffern, Marie C ^a   Park, Hyo Min ^b   Au Yeung, Ho Yu ^a   Van De Bittner, Genevieve C ^a   Ackerman, Cheri M ^a   Stahl, Andreas ^b   Chang, Christopher J ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c AGILENT TECHNOLOGIES   (United States)

Author keywords

Copper; Luciferin; Metabolic liver disease; Metal homeostasis; Molecular imaging

Indexed keywords

CARRIER PROTEIN; COPPER; COPPER CAGED LUCIFERIN 1; FIREFLY LUCIFERASE; LUCIFERIN; UNCLASSIFIED DRUG; LUMINESCENT AGENT; METALLOCHAPERONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BIOLUMINESCENCE; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED STUDY; COPPER DEFICIENCY; DRUG MEGADOSE; DRUG SELECTIVITY; DRUG SYNTHESIS; GLUCOSE INTOLERANCE; IN VIVO STUDY; MOLECULAR IMAGING; MOLECULAR PROBE; MOUSE; MURINE MODEL; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE SPECIFICITY; WEIGHT GAIN; ANIMAL; DEFICIENCY; DIAGNOSTIC IMAGING; LIPID DIET; LUMINESCENCE; MALE; METABOLISM; PROCEDURES; TRANSGENIC MOUSE;

ANIMALS; COPPER; DIET, HIGH-FAT; FIREFLY LUCIFERIN; LUMINESCENT AGENTS; LUMINESCENT MEASUREMENTS; MALE; METALLOCHAPERONES; MICE; MICE, TRANSGENIC; MOLECULAR IMAGING; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 85005949394     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1613628113     Document Type: Article

References (65)

1. Ferguson-Miller S, Babcock GT (1996) Heme/copper terminal oxidases. Chem Rev 96(7):2889-2908.
2. Ishida S, Andreux P, Poitry-Yamate C, Auwerx J, Hanahan D (2013) Bioavailable copper modulates oxidative phosphorylation and growth of tumors. Proc Natl Acad Sci USA 110(48):19507-19512.
3. McCord JM, Fridovich I (1969) Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J Biol Chem 244(22):6049-6055.
4. Reddi AR, Culotta VC (2013) SOD1 integrates signals from oxygen and glucose to repress respiration. Cell 152(1-2):224-235.
5. Kohen A, Klinman JP (1998) Enzyme catalysis: Beyond classical paradigms. Acc Chem Res 31(7):397-404.
6. Herranz N, et al. (2012) Lysyl oxidase-like 2 deaminates lysine 4 in histone H3. Mol Cell 46(3):369-376.
7. Brady DC, et al. (2014) Copper is required for oncogenic BRAF signalling and tumorigenesis. Nature 509(7501):492-496.
8. Turski ML, et al. (2012) A novel role for copper in Ras/mitogen-activated protein kinase signaling. Mol Cell Biol 32(7):1284-1295.
9. Chang CJ (2015) Searching for harmony in transition-metal signaling. Nat Chem Biol 11(10):744-747.
10. Dodani SC, et al. (2014) Copper is an endogenous modulator of neural circuit spontaneous activity. Proc Natl Acad Sci USA 111(46):16280-16285.
11. Krishnamoorthy L, et al. (2016) Copper regulates cyclic-AMP-dependent lipolysis. Nat Chem Biol 12(8):586-592.
12. You H, et al. (2012) Aβ neurotoxicity depends on interactions between copper ions, prion protein, and N-methyl-D-aspartate receptors. Proc Natl Acad Sci USA 109(5): 1737-1742.
13. Kaler SG (2011) ATP7A-related copper transport diseases-emerging concepts and future trends. Nat Rev Neurol 7(1):15-29.
14. Camakaris J, Voskoboinik I, Mercer JF (1999) Molecular mechanisms of copper homeostasis. Biochem Biophys Res Commun 261(2):225-232.
15. Puig S, Thiele DJ (2002) Molecular mechanisms of copper uptake and distribution. Curr Opin Chem Biol 6(2):171-180.
16. Aron AT, Ramos-Torres KM, Cotruvo JA Jr, Chang CJ (2015) Recognition- And reactivity- based fluorescent probes for studying transition metal signaling in living systems. Acc Chem Res 48(8):2434-2442.
17. Kozlowski H, Janicka-Klos A, Brasun J (2009) Copper, iron, and zinc ions homeostasis and their role in neurodegenerative disorders (metal uptake, transport, distribution and regulation). Coord Chem Rev 253(21-22):2665-2685.
18. Wang Y, Hodgkinson V, Zhu S, Weisman GA, Petris MJ (2011) Advances in the understanding of mammalian copper transporters. Adv Nutr 2(2):129-137.
19. Huster D, Lutsenko S (2007) Wilson disease: Not just a copper disorder. Analysis of a Wilson disease model demonstrates the link between copper and lipid metabolism. Mol Biosyst 3(12):816-824.
20. Desai V, Kaler SG (2008) Role of copper in human neurological disorders. Am J Clin Nutr 88(3):855S-858S.
21. Carr TP, Lei KY (1990) High-density lipoprotein cholesteryl ester and protein catabolism in hypercholesterolemic rats induced by copper deficiency. Metabolism 39(5): 518-524.
22. Stättermayer AF, et al. (2015) Hepatic steatosis in Wilson disease-Role of copper and PNPLA3 mutations. J Hepatol 63(1):156-163.
23. Huster D, et al. (2007) High copper selectively alters lipid metabolism and cell cycle machinery in the mouse model of Wilson disease. J Biol Chem 282(11):8343-8355.
24. Aigner E, et al. (2010) A role for low hepatic copper concentrations in nonalcoholic fatty liver disease. Am J Gastroenterol 105(9):1978-1985.
25. Aigner E, et al. (2008) Copper availability contributes to iron perturbations in human nonalcoholic fatty liver disease. Gastroenterology 135(2):680-688.
26. Aigner E, Weiss G, Datz C (2015) Dysregulation of iron and copper homeostasis in nonalcoholic fatty liver. World J Hepatol 7(2):177-188.
27. Feldman A, Aigner E, Weghuber D, Paulmichl K (2015) The potential role of iron and copper in pediatric obesity and nonalcoholic fatty liver disease. BioMed Res Int 2015(2):287401.
28. Gong D, et al. (2008) A copper(II)-selective chelator ameliorates diabetes-evoked renal fibrosis and albuminuria, and suppresses pathogenic TGF-β activation in the kidneys of rats used as a model of diabetes. Diabetologia 51(9):1741-1751.
29. Engle TE (2011) Copper and lipid metabolism in beef cattle: A review. J Anim Sci 89(2): 591-596.
30. Burkhead JL, Lutsenko S (2013) The Role of Copper as a Modifier of Lipid Metabolism. Available at www.intechopen.com/books/lipid-metabolism/the-role-of-copper-as-amodifier-of-lipid-metabolism. Accessed November 12, 2016.
31. Fahrni CJ (2013) Synthetic fluorescent probes for monovalent copper. Curr Opin Chem Biol 17(4):656-662.
32. Cotruvo JA Jr, Aron AT, Ramos-Torres KM, Chang CJ (2015) Synthetic fluorescent probes for studying copper in biological systems. Chem Soc Rev 44(13):4400-4414.
33. Ramos KM, Kolemen S, Chang CJ (2016) Thioether coordination chemistry for molecular imaging of copper in biological systems. Isr J Chem 56(9-10):724-737.
34. Bourassa D, et al. (2014) 3D imaging of transition metals in the zebrafish embryo by X-ray fluorescence microtomography. Metallomics 6(9):1648-1655.
35. Torres JB, et al. (2016) PET Imaging of copper trafficking in a mouse model of Alzheimer disease. J Nucl Med 57(1):109-114.
36. Hong-Hermesdorf A, et al. (2014) Subcellular metal imaging identifies dynamic sites of Cu accumulation in Chlamydomonas. Nat Chem Biol 10(12):1034-1042.
37. Peng F (2014) Positron emission tomography for measurement of copper fluxes in live organisms. Ann N Y Acad Sci 1314:24-31.
38. Que EL, et al. (2009) Copper-responsive magnetic resonance imaging contrast agents. J Am Chem Soc 131(24):8527-8536.
39. Hirayama T, Van de Bittner GC, Gray LW, Lutsenko S, Chang CJ (2012) Near-infrared fluorescent sensor for in vivo copper imaging in a murine Wilson disease model. Proc Natl Acad Sci USA 109(7):2228-2233.
40. Li J, Chen L, Du L, Li M (2013) Cage the firefly luciferin!-A strategy for developing bioluminescent probes. Chem Soc Rev 42(2):662-676.
41. Paley MA, Prescher JA (2014) Bioluminescence: A versatile technique for imaging cellular and molecular features. Med Chem Comm 5(3):255-267.
42. Prescher JA, Contag CH (2010) Guided by the light: Visualizing biomolecular processes in living animals with bioluminescence. Curr Opin Chem Biol 14(1):80-89.
43. Kircher MF, Gambhir SS, Grimm J (2011) Noninvasive cell-tracking methods. Nat Rev Clin Oncol 8(11):677-688.
44. O'Neill K, Lyons SK, Gallagher WM, Curran KM, Byrne AT (2010) Bioluminescent imaging: A critical tool in pre-clinical oncology research. J Pathol 220(3):317-327.
45. Van de Bittner GC, Bertozzi CR, Chang CJ (2013) Strategy for dual-analyte luciferin imaging: In vivo bioluminescence detection of hydrogen peroxide and caspase activity in a murine model of acute inflammation. J Am Chem Soc 135(5):1783-1795.
46. Godinat A, et al. (2013) A biocompatible in vivo ligation reaction and its application for noninvasive bioluminescent imaging of protease activity in living mice. ACS Chem Biol 8(5):987-999.
47. Van de Bittner GC, Dubikovskaya EA, Bertozzi CR, Chang CJ (2010) In vivo imaging of hydrogen peroxide production in a murine tumor model with a chemoselective bioluminescent reporter. Proc Natl Acad Sci USA 107(50):21316-21321.
48. Sellmyer MA, et al. (2013) Visualizing cellular interactions with a generalized proximity reporter. Proc Natl Acad Sci USA 110(21):8567-8572.
49. Porterfield WB, Jones KA, McCutcheon DC, Prescher JA (2015) A "caged" luciferin for imaging cell-cell contacts. J Am Chem Soc 137(27):8656-8659.
50. Mofford DM, Adams ST Jr, Reddy GSKK, Reddy GR, Miller SC (2015) Luciferin amides enable in vivo bioluminescence detection of endogenous fatty acid amide hydrolase activity. J Am Chem Soc 137(27):8684-8687.
51. Taki M, Iyoshi S, Ojida A, Hamachi I, Yamamoto Y (2010) Development of highly sensitive fluorescent probes for detection of intracellular copper(I) in living systems. J Am Chem Soc 132(17):5938-5939.
52. Au-Yeung HY, Chan J, Chantarojsiri T, Chang CJ (2013) Molecular imaging of labile iron(II) pools in living cells with a turn-on fluorescent probe. J Am Chem Soc 135(40): 15165-15173.
53. Au-Yeung HY, New EJ, Chang CJ (2012) A selective reaction-based fluorescent probe for detecting cobalt in living cells. Chem Commun (Camb) 48(43):5268-5270.
54. Park H, et al. (October 11, 2016) A system for in vivo imaging of hepatic free fatty acid uptake. Gastroenterology, 10.1053/j.gastro.2016.10.002.
55. Leslie M (2015) The liver's weighty problem. Science 349(6243):18-20.
56. Uppal V, Mansoor S, Furuya KN (2016) Pediatric non-alcoholic fatty liver disease. Curr Gastroenterol Rep 18(5):24.
57. Lee CH, Lam KSL (June 4, 2016) Managing non-alcoholic fatty liver disease in diabetes: Challenges and opportunities. J Diabetes Invest, 10.1111/jdi.12534.
58. Rinella ME, et al. (2014) Controversies in the diagnosis and management of NAFLD and NASH. Gastroenterol Hepatol (N Y) 10(4):219-227.
59. Hardy T, Oakley F, Anstee QM, Day CP (2016) Nonalcoholic fatty liver disease: Pathogenesis and disease spectrum. Annu Rev Pathol 11:451-496.
60. Church SJ, et al. (2015) Deficient copper concentrations in dried-defatted hepatic tissue from ob/ob mice: A potential model for study of defective copper regulation in metabolic liver disease. Biochem Biophys Res Commun 460(3):549-554.
61. Sato A, et al. (2010) Antiobesity effect of eicosapentaenoic acid in high-fat/highsucrose diet-induced obesity: Importance of hepatic lipogenesis. Diabetes 59(10): 2495-2504.
62. Wang C-Y, Liao JK (2012) A mouse model of diet-induced obesity and insulin resistance. Methods Mol Biol 821:421-433.
63. Kim B-E, et al. (2010) Cardiac copper deficiency activates a systemic signaling mechanism that communicates with the copper acquisition and storage organs. Cell Metab 11(5):353-363.
64. Bertinato J, Iskandar M, L'Abbé MR (2003) Copper deficiency induces the upregulation of the copper chaperone for Cu/Zn superoxide dismutase in weanling male rats. J Nutr 133(1):28-31.
65. Prohaska JR, Broderius M, Brokate B (2003) Metallochaperone for Cu, Zn-superoxide dismutase (CCS) protein but not mRNA is higher in organs from copper-deficient mice and rats. Arch Biochem Biophys 417(2):227-234.